# US 2020/0400681 A1 · Method for quantitatively determining a therapeutic tnf-alpha inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0400681 A1
- Document ID: US20200400681A1
- Status: Published application
- Kind: A1
- Application number: 16/962,566
- Filed: 2019-01-14
- Published: 2020-12-24
- Earliest claimed: 2018-01-17
- Assignees: Siemens Healthcare Diagnostics Products GmbH
- Applicants: Siemens Healthcare Diagnostics Products GmbH
- Inventors: Harald ALTHAUS; Thorsten KELLER
- Web page: https://patentgrep.com/patent/US20200400681A1

## CPC

- G01N 33/54313: {the carrier being characterised by its particulate form}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/5434: {using magnetic particle immunoreagent carriers which constitute new materials per se}
- G01N 2333/525: Tumor necrosis factor [TNF]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention is in the field of in vitro diagnostics and relates to a method for quantitatively determining therapeutic TNF-alpha inhibitors.

## Claims

### Claim 1

A method for quantitatively determining a therapeutic TNF-alpha inhibitor in a sample, the method comprising the steps of:
a) providing a reaction mixture by contacting the sample
i. with isolated, free TNF-alpha protein and then
ii. with a first TNF-alpha binding partner;
b) determining the amount of a complex which forms in the reaction mixture and is composed of TNF-alpha protein and the first TNF-alpha binding partner; and
c) determining the amount of the therapeutic TNF-alpha inhibitor in the sample by comparing the amount of the complex composed of TNF-alpha protein and the first TNF-alpha binding partner determined in the reaction mixture with amounts of a complex composed of TNF-alpha protein and the first TNF-alpha binding partner in reaction mixtures containing samples having known concentrations of a TNF-alpha binding partner.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the first TNF-alpha binding partner is associated with a particulate solid phase and wherein the amount of the complex which forms in the reaction mixture and is composed of TNF-alpha protein and the first TNF-alpha binding partner in the reaction mixture is determined by measuring agglutination of the particulate solid phase in the reaction mixture.

### Claim 3 (depends on 2)

The method as claimed in claim 2, wherein the agglutination of the particulate solid phase in the reaction mixture is measured photometrically.

### Claim 4 (depends on 2)

The method as claimed in claim 2, wherein a first fraction of the particulate solid phase is associated with a first component of a signal-forming system and a second fraction of the particulate solid phase is associated with a second component of the signal-forming system and wherein the first component and the second component of the signal-forming system cooperate such that a detectable signal forms when the first component and the second component of the signal-forming system are brought into close proximity to one another and the agglutination of the particulate solid phase in the reaction mixture is measured on the basis of the signal formed.

### Claim 5 (depends on 4)

The method as claimed in claim 4, wherein the first component of the signal-forming system is a chemiluminescent agent and the second component of the signal-forming system is a photosensitizer, or vice versa, and wherein the chemiluminescence in the reaction mixture is measured.

### Claim 6 (depends on 1)

The method as claimed in claim 1, wherein the first TNF-alpha binding partner is associated with a solid phase and wherein the amount of the complex which forms in the reaction mixture and is composed of TNF-alpha protein and the first TNF-alpha binding partner is determined in step b) by removing the reaction mixture from the solid phase and subsequently contacting the solid phase with a second TNF-alpha binding partner and measuring the amount of the second TNF-alpha binding partner which is bound to the complex which was formed in the reaction mixture and is associated with the solid phase and is composed of TNF-alpha protein and the first TNF-alpha binding partner.

### Claim 7 (depends on 6)

The method as claimed in claim 6, wherein the second TNF-alpha binding partner is associated with a component of a signal-forming system.

### Claim 8 (depends on 6)

The method as claimed in claim 6, wherein the reaction mixture is incubated for a period of from 1 second to 10 minutes after contacting the sample with isolated, free TNF-alpha protein and before adding the first TNF-alpha binding partner.

### Claim 9 (depends on 6)

The method as claimed in claim 6, wherein the first and/or the second TNF-alpha binding partner is an anti-TNF-alpha antibody.

### Claim 10

An assay kit for use in a method for quantitatively determining a therapeutic TNF-alpha inhibitor in a sample, which contains the following components:
a) a first vessel containing a reagent, the reagent containing 50 μg-2 mg/L isolated, free TNF-alpha protein; and
b) a second vessel containing a first TNF-alpha binding partner.

### Claim 11 (depends on 10)

The assay kit as claimed in claim 10, wherein the first TNF-alpha binding partner in the second vessel is associated with a particulate solid phase.

### Claim 12 (depends on 11)

The assay kit as claimed in claim 11, wherein the particulate solid phase are latex particles.

### Claim 13 (depends on 11)

The assay kit as claimed in claim 11, further comprising:
c) a third vessel containing a particulate solid phase which is coated with the first or with a second TNF-alpha binding partner,
wherein the particulate solid phase in the second vessel is associated with a first component of a signal-forming system and the particulate solid phase in the third vessel is associated with a second component of the signal-forming system and wherein the first component and the second component of the signal-forming system cooperate such that a detectable signal forms when the first component and the second component of the signal-forming system are brought into close proximity to one another.

### Claim 14 (depends on 13)

The assay kit as claimed in claim 13, wherein the first component of the signal-forming system is a chemiluminescent agent and the second component of the signal-forming system is a photosensitizer, or vice versa.

### Claim 15 (depends on 10)

The assay kit as claimed in claim 10, wherein the first TNF-alpha binding partner in the second vessel is associated with a surface of the second vessel.

### Claim 16 (depends on 15)

The assay kit as claimed in claim 15, further comprising:
c) a third vessel containing a second TNF-alpha binding partner.

### Claim 17 (depends on 16)

The assay kit as claimed in claim 16, wherein the second TNF-alpha binding partner is associated with a component of a signal-forming system.

### Claim 18 (depends on 10)

The assay kit as claimed in claim 10, wherein the TNF-alpha protein present in the first reagent is a recombinant TNF-alpha protein.

### Claim 19 (depends on 10)

The assay kit as claimed in claim 10, wherein the first TNF-alpha binding partner in the second vessel is an anti-TNF-alpha antibody.

### Claim 20 (depends on 19)

The assay kit as claimed in claim 19, wherein the anti-TNF-alpha antibody is a monoclonal anti-TNF-alpha antibody.
